Generic Name and Formulations:
Cetrorelix (as acetate) 0.25mg, 3mg; per vial; pwd for SC inj after reconstitution.
EMD Serono, Inc.
Indications for CETROTIDE:
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for in vitro fertilization.
Give by SC inj into lower abdominal wall during early to mid-follicular phase; see literature. 3mg once on stimulation day 7, or 0.25mg daily beginning on stimulation day 5 or 6 and continuing until day of hCG administration.
Pregnancy (Cat.X). Nursing mothers.
Do complete gynecological and endocrinological exam first.
Ovarian hyperstimulation syndrome, nausea, headache, inj site reactions, elevated enzymes (eg, ALT, alkaline phosphatase).
Vials 0.25mg (w. diluent)—1
3mg (w. diluent)—1
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|